Tsfg, LLC Genmab A/S Transaction History

Tsfg, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Apr 14, 2021	SELL	$30.92 - $44.4 $1,515 - $2,175	-49 Closed	0 $0
Q3 2020 Oct 06, 2020	SELL	$33.07 - $38.68 $529 - $618	-16 Reduced 24.62%	49 $2,000
Q2 2020 Jul 07, 2020	SELL	$20.05 - $33.89 $581 - $982	-29 Reduced 30.85%	65 $2,000
Q1 2020 Apr 08, 2020	SELL	$17.15 - $25.22 $360 - $529	-21 Reduced 18.26%	94 $2,000
Q4 2019 Jan 27, 2020	SELL	$18.88 - $24.14 $245 - $313	-13 Reduced 10.16%	115 $3,000
Q3 2019 Jan 27, 2020	BUY	$18.0 - $21.38 $2,304 - $2,736	128 New	128 $3,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Tsfg, LLC, based on Form 13F filings with the SEC.

Stay updated on Tsfg, LLC with notifications on news.